Decoy

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

Retrieved on: 
星期一, 三月 25, 2024
Toxicity, B cell, CD8, Research, Cancer research, AACR, Chemokine, Therapy, Cytokine, Immune system, Poster, Viral, Decoy, Bacteria, Vaccine

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces that Dr. Michael Newman, Founder and Chief Scientific Officer of Indaptus, will present a poster at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego on Wednesday morning, April 10th. An abstract of the data to be presented has been published online in the AACR Journal, Cancer Research. The data confirm and significantly extend the proposed mechanism of action of the Company’s proprietary platform technology of attenuated and killed, non-pathogenic bacteria containing multiple immune receptor agonists for pulsed anti-tumor immunotherapy.

Key Points: 
  • An abstract of the data to be presented has been published online in the AACR Journal, Cancer Research.
  • The data confirm and significantly extend the proposed mechanism of action of the Company’s proprietary platform technology of attenuated and killed, non-pathogenic bacteria containing multiple immune receptor agonists for pulsed anti-tumor immunotherapy.
  • The activity was associated with induction of human tumor cell killing by Decoy bacteria in the presence of immune cells.
  • Potentially unacceptable toxicity from this breadth of immune activation is avoided by using systemically administered killed bacteria as a delivery vehicle.

Brunswick Exploration Provides Update on Ontario, Manitoba and Saskatchewan Projects

Retrieved on: 
星期一, 八月 28, 2023
Reindeer, Reindeer Lake, BRW, Trans-Hudson orogeny, Atlantic Canada, Fire, Firefly, Mantis, TSX, Lithium, Eeyou Istchee, Maple syrup, Hanson Lake, Decoy, Western Canada

MONTREAL, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Brunswick Exploration Inc. (TSX-V: BRW; “BRW” or the “Company”) is pleased to provide an update on all 2023 exploration programs that were completed in the provinces of Ontario, Manitoba and Saskatchewan.

Key Points: 
  • MONTREAL, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Brunswick Exploration Inc. (TSX-V: BRW; “BRW” or the “Company”) is pleased to provide an update on all 2023 exploration programs that were completed in the provinces of Ontario, Manitoba and Saskatchewan.
  • Mr. Killian Charles, President and CEO of BRW, commented: “All exploration programs were successful in rapidly testing multiple targets by prospecting, diamond drilling and stripping.
  • BRW will be putting all projects in Ontario, Manitoba and Saskatchewan on pause and assessing the next steps while refocusing all of our manpower and exploration efforts in the Eeyou Istchee-James Bay for the coming months.
  • He is a Professional Geologist registered in Saskatchewan, Manitoba, Ontario, New Brunswick, Nova Scotia, and Newfoundland.

Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer

Retrieved on: 
星期一, 八月 7, 2023
American literature, Drug development, Faculty of Tropical Medicine, Mahidol University, Therapy, Nilotinib, Decoy, Business administration, Hospital, Novartis, Patient, Columbia Business School, Brown University, Immunotoxin, Pharmaceutical industry

NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announces the appointment of Roger Waltzman, M.D.

Key Points: 
  • NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announces the appointment of Roger Waltzman, M.D.
  • as its Chief Medical Officer, effective August 7, 2023.
  • Jeffrey Meckler, Indaptus’ CEO commented, “Roger’s deep experience in drug development, particularly in the field of immuno-oncology, and his time as an officer at development and clinical-stage companies makes him an ideal candidate to assume the position of chief medical officer at Indaptus.
  • Prior, he served in the c-suite as Chief Medical Officer at Rgenix, Inc. (now Inspirna, Inc) and as Chief Scientific Officer at Jaguar Health.

Indaptus Therapeutics’ Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit

Retrieved on: 
星期一, 五月 1, 2023
Cytosol, Toxicity, Therapy, NOD, Infection, Clinical trial, Cancer, American Association for Cancer Research, Research, Neoplasm, Inflammation, Decoy, Patient, PRR, Poster, TLR, Pharmaceutical industry, Vaccine

The research discussed is also reflective of the recently presented poster during the American Association for Cancer Research, presented April 18th.

Key Points: 
  • The research discussed is also reflective of the recently presented poster during the American Association for Cancer Research, presented April 18th.
  • Dr. Newman’s second talk, “Pre-Clinical Anti-HBV Activity with a Passively Targeted, Multi-TLR, NOD and STING Agonist,” which features the Company’s infectious disease research on its Decoy platform will be held on May 11th at 2:30PM.
  • Deep diving into the role that the microbiome plays in innate immune regulation to provide a more holistic overview of how the STING and TLR activation are regulated.
  • The event will be held at the Hilton Boston Back Bay in Boston.

Indaptus Therapeutics Receives Brazilian Patent Allowance for Decoy Platform

Retrieved on: 
星期一, 四月 17, 2023
Decoy, Therapy, Industrial property, Patent, Patient, Pharmaceutical industry

NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces it has received a patent allowance on Application #1120150158323 from the National Institute of Industrial Property of Brazil for its Decoy immunotherapy platform.

Key Points: 
  • NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces it has received a patent allowance on Application #1120150158323 from the National Institute of Industrial Property of Brazil for its Decoy immunotherapy platform.
  • The allowed patent includes a disease agnostic independent composition claim covering the Decoy platform.
  • Jeffrey Meckler, Indaptus’ CEO commented, “We are pleased with the increasing global reach of the patents being issued for our Decoy platform, with most major countries now having granted patents.
  • We expect to continue to strengthen our intellectual property estate for the Decoy platform, providing additional value for shareholders.

Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Retrieved on: 
星期二, 十二月 13, 2022
Immunotherapy, Liver, Cell, Neoplasm, Annual report, MTD, Incidence, Inflammation, Therapy, Security (finance), Government, TLR, Spleen, Safety, Immunology, Science, HBV, Squamous cell carcinoma, Toxicity, Toxicology, HIV, Immune system, Infection, IND, Cancer, Risk, Index (publishing), Patient, Gram-negative bacteria, Pharmaceutical industry, Vaccine, Decoy

NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces the initiation of INDP-D101, its first-in-human, open label, dose escalation and expansion, multicenter Phase 1 clinical trial of its lead compound Decoy20 in patients with advanced/metastatic solid tumors.

Key Points: 
  • NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces the initiation of INDP-D101, its first-in-human, open label, dose escalation and expansion, multicenter Phase 1 clinical trial of its lead compound Decoy20 in patients with advanced/metastatic solid tumors.
  • We look forward to advancing to the expansion portion of the trial once the appropriate dose is identified,” said Boyan Litchev, M.D., Chief Medical Officer, Indaptus.
  • The Phase 1 study will begin with a single dose escalation part followed by an expansion part with continuous administration of Decoy20.
  • The study will enroll patients with advanced/metastatic solid tumors, who have exhausted the other known treatment options.

Indaptus Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
星期四, 十一月 10, 2022
GLOBE, Private Securities Litigation Reform Act, Forward-looking statement, IND, U.S. Securities and Exchange Commission, HBV, Squamous cell carcinoma, Food, Nasdaq, Immunotherapy, Risk, Neoplasm, Technology, Regulation of tobacco by the U.S. Food and Drug Administration, Therapy, Gram-negative bacteria, SEC, Annual report, Safety, Policy, Inflammation, Company, Toxicity, Immunology, Government, Clinical trial, Research, Liver, Patient, Immune system, Infection, Security (finance), Spleen, HIV, Toxicology, Pharmaceutical industry, Decoy

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announces financial results for the third quarter ended September 30, 2022 and provides a corporate update.

Key Points: 
  • NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (Indaptus or the Company), today announces financial results for the third quarter ended September 30, 2022 and provides a corporate update.
  • The study protocol allows for exploration of additional dosing regimens, including continuous weekly administration after initial safety has been established.
  • Decoy20 has the potential to treat a wide range of solid tumors including hepatocellular, colorectal and pancreatic carcinomas.
  • As of September 30, 2022, the Company had cash, cash equivalents and marketable securities of approximately $28.5 million.

Indaptus Therapeutics to Present at the LD Micro Main Event XV

Retrieved on: 
星期二, 十月 18, 2022
U.S. Securities and Exchange Commission, Risk, SEC, Webcast, Therapy, Government, IND, Gram-negative bacteria, Neoplasm, Infection, Annual report, Spleen, Security (finance), Inflammation, Technology, Private Securities Litigation Reform Act, HIV, Immune system, Toxicity, Immunotherapy, Liver, HBV, Forward-looking statement, Immunology, Toxicology, Squamous cell carcinoma, Vaccine, Decoy

A replay of the webcast will be archived and available following the event for approximately 90 days.

Key Points: 
  • A replay of the webcast will be archived and available following the event for approximately 90 days.
  • Indaptus Therapeutics has evolved from more than a century of immunotherapy advances.
  • Indaptus patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, with reduced i.v.
  • toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity.

Brunswick Exploration Options Lithium-Bearing Pegmatite in Ontario

Retrieved on: 
星期一, 十月 3, 2022
GLOBE, Property, LCT, News, TSX Venture Exchange, Effective date, Industry, Legislation, Atlantic Canada, Metal, Option, Hearst, Ontario, SEDAR, Corporation, NSR, Agreement, Project, BRW, Lithium, Cell, Last Resort, Forestry, Exercise, Sale, Lowther, Acquisition, TSX, Intention, Company, Bookkeeping, Life insurance, Car rental, Decoy, Atlantic Ocean

Ontario is also very prospective for lithium exploration and we believe the Hearst area is a fantastic location with great access to infrastructure.

Key Points: 
  • Ontario is also very prospective for lithium exploration and we believe the Hearst area is a fantastic location with great access to infrastructure.
  • Brunswick Exploration has concurrently optioned the Lowther II Regional Property from Last Resort Resources Limited, containing 154 claims totaling 3,235 hectares.
  • Brunswick Exploration will retain a further right to repurchase the remaining 1% NSR for $2,000,000 for a period of two years following the initial repurchase.
  • The scientific and technical information contained in this press release has been reviewed and approved by Mr. Charles Kodors, Manager Atlantic Canada of Brunswick Exploration.

Indaptus Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference

Retrieved on: 
星期二, 九月 6, 2022
Inflammation, Neoplasm, Security (finance), Spleen, HBV, Technology, Gram-negative bacteria, IND, Therapy, Liver, Government, Toxicity, Squamous cell carcinoma, SEC, Infection, U.S. Securities and Exchange Commission, HIV, Immunotherapy, Immune system, Toxicology, Risk, Annual report, Private Securities Litigation Reform Act, Immunology, Forward-looking statement, Vaccine, Risk management, Decoy

Indaptus patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, with reduced i.v.

Key Points: 
  • Indaptus patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, with reduced i.v.
  • toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity.
  • Tumor eradication has been observed with Decoy products in combination with anti-PD-1 checkpoint therapy, low-dose chemotherapy or an approved targeted antibody.
  • Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made.